Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
202.44+1.27 (+0.63%)
At close: 04:00PM EST
202.48 +0.04 (+0.02%)
After hours: 07:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close201.17
Open201.38
Bid202.00 x 1100
Ask202.50 x 1100
Day's Range200.84 - 203.80
52 Week Range198.64 - 276.69
Volume3,569,883
Avg. Volume2,775,960
Market Cap116.313B
Beta (5Y Monthly)0.68
PE Ratio (TTM)16.77
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield7.04 (3.37%)
Ex-Dividend DateAug 16, 2021
1y Target EstN/A
  • PR Newswire

    Amgen Announces New Data Being Presented At ASH 2021

    Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021.

  • PR Newswire

    Amgen Announces 10% Increase In 2022 First Quarter Dividend

    Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. This represents a 10% increase from that paid in each of the previous four quarters.

  • PR Newswire

    Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

    Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static

Advertisement
Advertisement